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Examining Fluoxetine Treatment for Selective Mutism in Children 
Selective mutism (SM), previously referred to as elective mutism, is a disorder that is 
classified by the refusal or failure to talk in one or more social situations, despite the 
mental capacity and physical ability to comprehend and participate in spoken language 
(Black & Uhde, 1994). While this disorder can be extremely debilitating to the children 
affected, there is little known about this disorder. This is largely because there were no 
studies describing etiology, history, characteristics and treatment of children with SM until 
around 1993 (Dummit, Klein, Tancer, Asche, & Martin, 1996). This disorder can negatively 
impact the ability to reach childhood developmental milestones, especially socially and 
academically, because of the lack of verbal communication. Because of these devastating 
effects in early childhood that can occur and shape the rest of a child’s education and social 
experiences, it is very important to learn more about this disorder and the treatment 
options. One treatment option has been to administer Fluoxetine, a selective serotonin 
reuptake inhibitor often used as an antidepressant or to help with anxiety symptoms. This 
paper will provide a review of the evidence of Fluoxetine as a treatment for selective 
mutism, and then critique the evidence in comparison with other treatment options. A 
short overview of etiology and background will be provided, followed by an overview of 
treatments available for SM and an explanation of fluoxetine treatment. The literature 
regarding fluoxetine treatment will then be critiqued. The side effects of fluoxetine in 
comparison to other pharmacotherapy options will be discussed and finally, other non-
pharmacotherapy options will be examined. 
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Etiology of Selective Mutism 
Selective mutism is characterized by a failure to speak in social situations or respond 
when spoken to. The Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM–5; 
American Psychiatric Association, 2013) states that this failure to speak must interfere 
with communication in a variety of settings (social, academic) for at least one month, and 
that it cannot be due to a lack of knowledge of spoken language. This disorder is rare, with 
a prevalence of between .03 – 1%. It usually begins before five years of age, and persistence 
varies with each individual. Some children ‘outgrow’ it with time, and others require 
clinical intervention in order to be successful in academic or social environments. In many 
cases, the symptoms of SM may disappear, but symptoms of another anxiety disorder may 
still exist, often social anxiety or social phobia (American Psychiatric Association, 2013). 
The causes are largely unknown; some parenting factors may play a role in development, 
such as demonstrating social inhibition or overprotective parenting, as well as negative 
affectivity of the child, or other possible language difficulties. Most frequently, other 
anxiety disorders or oppositional defiant disorder have been known to be comorbid with 
selective mutism. Overall, there is little conclusive information known about the cause and 
course of this disorder, and more research needs to be done in order to gain more insight 
about the disorder itself and how to treat it.  
Treatments Available 
Many different kinds of psychosocial and pharmacological interventions have been 
utilized for the treatment of selective mutism in children. Psychosocial interventions have 
included behavioral therapy, group therapy, family therapy, and intensive programs 
focusing on multimodal psychosocial treatment (Manassis, 2009). Many case reports have 
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studied these types of treatment, as well as a few large-scale studies, with findings that 
support these treatment options when administered appropriately (Harvey & Milne, 1998; 
Wright et al., 1995; Manassis, 2009). There is more data supporting behavioral and 
multimodal treatments because of the larger research base for these, and cognitive 
behavioral therapy is thought to be a positive treatment option for children who are older 
than 8 years (Manassis, 2009). Generally these types of treatments are the first ones tried 
when treating children with selective mutism. 
There has also been research regarding pharmacotherapy for selective mutism in 
children, most frequently involving SSRIs or other medications known to be helpful in 
treating social phobia, a closely related disorder (Dow, Sonies, Scheib, & Moss, 1996). One 
type of MAOI medication used as treatment for SM is phenelzine. This drug seems to have 
some positive treatment effects, however, there are significant food, dietary, and drug 
interactions and restrictions associated with its use, making it a less-than-ideal option for 
children (Kaakeh & Stumpf, 2008).  Common SSRIs used include fluvoxamine, sertraline, 
paroxetine, and fluoxetine. The first three listed have very few studies involving them as 
treatment at all, and the studies that are available lack standardization, randomization, and 
have had very small sample sizes. These factors are part of the reason there is a very small 
body of research findings regarding the use of these drugs as treatment. The most 
frequently administered and studied pharmacotherapy for selective mutism is fluoxetine. 
Fluoxetine Treatment Overview 
Pharmacological treatment of selective mutism often includes the administration of 
selective serotonin reuptake inhibitor (SSRI) medications because of their effects on closely 
related mood and anxiety disorders (Dow, Sonies, Scheib, & Moss, 1996). The most 
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commonly studied SSRI in the treatment of SM is fluoxetine, most likely because of the high 
efficacy it has showed when treating social phobia (Kaakeh & Stumpf, 2008). Fluoxetine 
has been regarded as an ideal medication for children, largely because of the minimal side 
effects associated with it, including markedly less sedation affects in comparison to other 
SSRIs (Harvey & Milne, 1998). In addition, the dosage of the drug allows for a variety of 
different titration methods and flexibility when being administered to children, which is 
extremely important for countering side-effects the drug may have in clinical studies. Many 
studies begin with a low dosage and slowly increase the medication, depending on the 
overall effects of the drug with each individual child. If negative side effects occur, dosage is 
lessened. 
Literature Review 
There are many literature reviews discussing studies of fluoxetine treatment in children 
with selective mutism, many of them agreeing of this as a valid treatment option. However, 
considering limited information is known about the efficacy of any drug therapy for this 
disorder, pharmacological treatment should usually be considered as a secondary 
treatment when psychotherapy alone has failed (Kaakeh & Stumpf, 2008). When 
pharmacological intervention is necessary, fluoxetine has more evidence of efficacy than 
other medications, likely because it has been studied more widely (Manassis, 2009). In 
many studies, dosages should start low and increase gradually with close monitoring. This 
is because it is easier to control positive and negative effects of the drug for the children it 
is being tested in. It is noted in some review articles of case studies that there are reports of 
‘positive effects’ of fluoxetine therapy, but minimal detail or explanation is given in these 
reports (Dow et al., 1996). This is important to note because it illustrates the necessity for 
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future research on this topic in order to understand if it is a safe and effective treatment 
option for children.  
The bulk of information on fluoxetine treatment for children with SM has been reported 
through case studies. Though low in efficacy and generalizability, they provide the 
groundwork needed for further research into this treatment. One of the most frequently 
cited case reports studied a 4 year old female named Leah, with pervasive symptoms of 
selective mutism that were not improved through an intensive preschool program focused 
on diagnosis and intervention of child disorders (Wright, Cuccaro, Leonhardt, Kendall, & 
Anderson, 1995). After the first five days of fluoxetine treatment at a beginning dose of 
4mg/day, Leah began to increase verbal communication in some environments. At the end 
of twenty days of treatment and with an increased dosage of 8mg/day, Leah was talking at 
an age-appropriate level in all settings.  
Other case studies report similar findings of positive improvement regarding verbal 
communication increases with varying time frames of the children responding to fluoxetine 
(Harvey & Milne, 1998; Silveira, Jainer, & Bates, 2004). All case studies in this review 
administered fluoxetine treatment only after participant’s symptoms were not improved 
through other interventions, such as behavior therapy, intensive programs, and 
psychotherapy. Detailed accounts of these individual case studies are important for piloting 
future experiments of fluoxetine treatment for children with selective mutism.  
Manassis and Tannock, working with many other researchers, have published multiple 
sources regarding selective mutism and fluoxetine treatment. A correlational study they 
published examines many language, cognitive, and anxiety symptoms in comparison with 
children who have a diagnosis of selective mutism and/or other anxiety disorders 
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(Manassis et al., 2007). The results from this study were used as the basis for a study that 
utilized a portion of the same participants for a quasi-experimental design study comparing 
treatments for selective mutism (Manassis & Tannock, 2008). All participants received 
school interventions for an amount of time, and then slightly more than half also began 
receiving SSRIs. All but two participants were administered fluoxetine at dosage 
appropriate on an individual basis. The children who were receiving medication treatment 
showed significantly more improvement of symptoms when compared to those who were 
not receiving medication. While it cannot be determined what the impact of medication 
alone is for selective mutism symptoms, the results of this study suggest some significant 
positive impact of administering medication and noticing a positive change in symptoms.  
Finally, there are only two well known experimental design studies published at this 
time that examine the impact of fluoxetine treatment on children with selective mutism. 
The first administered fluoxetine to a randomly assigned group of participants on a titrated 
schedule while receiving parental and teacher reports of symptoms over approximately 14 
weeks of the school year (Black & Uhde, 1994). The second study administered fluoxetine 
on a titration schedule for 9 weeks while measuring progress through weekly visits with 
the treating psychiatrist (Dummit et al., 1996). Each of these experiments found that 
fluoxetine was well tolerated in the children and seemed safe for the short amount of time 
that it was monitored. However, Black & Uhde found fluoxetine to be of limited usefulness, 
because their findings did not reach significant differences when compared to the control 
group regarding reports of parents and teachers (1994). Dummit et al. found significant 
improvement in symptoms, but the study did not control for other factors, it was difficult to 
determine what role the medication played in this improvement (1996). In each study, 
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minimal side effects were reported and symptoms for each individual seemed to improve 
for the better.  
Critique 
The research of fluoxetine treatment for children with selective mutism is not 
extensive, but is able to begin the discussion on this topic. The research at this time does 
not allow for a conclusion about the effectiveness or efficacy of fluoxetine treatment in 
children with SM to be determined. Some of the research has illustrated a correlation 
between administering SSRI medication and decreasing symptomology of selective mutism 
(Manassis & Tannock, 2008). However, with a lack of randomization and controlling for 
confounding variables including the impact of other treatments administered at the same 
time, this information should not be taken as concrete evidence.  
The bulk of information on this topic is derived from case studies involving one or two 
individuals. While case studies are beneficial and important to providing some insight onto 
a treatment option, they are extremely limited in offering information about a treatment 
option as a whole. While a case report can illustrate that a treatment option worked for an 
individual, such as with Leah who was discussed earlier (Wright et al., 1995), the 
information is not generalizable to other individuals with similar problems. Case studies 
simply do not provide enough information to safely determine if a treatment works or not.  
Slightly better in being able to determine outcomes of a specific treatment plan are 
quasi-experimental studies. Two of these studies have been done regarding selective 
mutism, with one of them focusing specifically on intervention options to help symptoms of 
the disorder (Manassis et al., 2007; Manassis & Tannock, 2008).  A correlation between 
symptoms of selective mutism and school intervention and/or medicinal intervention was 
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found. Children who were administered medication, including fluoxetine, were significantly 
improved in symptoms by the end of the study (Manassis & Tannock, 2008). However, 
because there was no randomization of participants into different groups, only a 
correlation between a decrease in SM symptoms and administration of SSRI medication can 
be determined at this time. As correlation does not equal causation, the only conclusion 
that can be made from this study is the negative correlation between administering SSRIs 
and decreasing symptoms; no information on the cause of this relationship can be 
determined. 
In addition, only two randomized control studies have been published at this time, with 
combined participants totaling 36 children. This alone is not consistent with the amount of 
participants necessary to determine a treatment’s efficacy within a controlled environment 
or the effectiveness for children in natural environments. The low participant numbers and 
the experimental designs of the information that is currently available regarding fluoxetine 
treatment for children with SM create significant limitations, and are a large reason that no 
concrete conclusions can be drawn about the efficacy or effectiveness of treatment.   
As stated, essentially all published information on fluoxetine treatment uses it as a 
secondary treatment plan. Reports vary on whether the initially administered treatment is 
continued or stopped when pharmacological treatment begins. Black & Uhde explicitly 
excluded participants who required other treatment during the time of the experiment, 
making their study one of the only ones that attempted to control for interference of other 
treatment while studying the effects of medication alone. Dummit et al. also controlled for 
confounding variables associated with other treatment by administering psychotherapy to 
any participants who had not previously received it and excluding those who responded to 
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it alone. Without controlling for the effects of other treatments while examining the 
treatment at hand, confounding variables can skew the data that is found from the study. 
While the low numbers and overall design of the studies examining fluoxetine 
treatment for SM are weaknesses of the research on this topic as a whole, there are some 
strengths within this research body. Fluoxetine has been regarded as a superior treatment 
option within pharmacotherapy as a whole because of the minimal side effects when 
compared to other types of SSRI or pharmacotherapy options as a whole (Harvey & Milne, 
1998). Additionally, as previously stated, Fluoxetine is the most frequently studied SSRI 
type of medication when administered to children with selective mutism diagnosis or 
symptoms (Kaakeh & Stumpf, 2008). This being said, there is more information known 
about this specific pharmacological treatment than there is about any other for selective 
mutism.  
There also seems to be evidence that fluoxetine should not be considered a primary 
treatment option. All of the individuals in the case studies mentioned were initially treated 
with differing kinds of behavioral therapy or intensive psychotherapy treatment programs 
before being administered fluoxetine as treatment (Harvey & Milne, 1998; Silveira et al., 
2004; Wright et al., 1995). Review articles also note that this treatment option should be 
considered for children with severe selective mutism that has been unresponsive to other 
types of interventions previously administered (Manassis, 2009). This consensus of 
fluoxetine as a secondary treatment option is a concrete strength of this body of research. 
In addition, there is a general consensus among all published studies that fluoxetine 
works in improving symptoms of selective mutism. While no concrete conclusions of 
efficacy or effectiveness can be drawn from this data, it gives a positive outlook on this 
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treatment option. It is the hope that vast future research will continue, specifically research 
that addresses the weaknesses of this body of research as a whole. More randomized, 
controlled experiments should be administered with larger sample sizes in order to 
effectively analyze the outcomes of fluoxetine treatment for children who are administered 
the drug for treatment of selective mutism. In these experiments, comparisons with other 
SSRIs, pharmacotherapy options, and psychological interventions should be examined 
separately in order to determine the best available treatment for children affected by SM. 
In addition, controls for co-morbidity, sex differences, and environmental factors need to 
be studied with the administration of fluoxetine to determine if this option is valid for 
certain populations or the generalized public as a whole. 
Conclusion 
Selective mutism is a debilitating childhood disorder that impacts developmental 
and academic milestones, as well as social relationships within the children who are 
affected. As illustrated through the studies cited in this paper, the information that is 
available largely supports the theory that fluoxetine has the potential to be a successful 
treatment for children with selective mutism and that there are few side-effects when 
administered correctly, but more information and research is necessary to be able to 
determine concrete conclusions. The literature suggests a consensus that this treatment 
option should be considered secondary, as providing young children with any type of 
pharmacological psychiatric treatment is often controversial and can have many negative 
impacts. In addition, there have been studies proving it’s efficacy as well as it’s 
effectiveness in treating symptoms of SM, but most of the literature available focuses on 
small sample sizes and short periods of assessment. For these reasons, the data is not 
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generalizable or significant enough to determine if this is a truly valid treatment option for 
children.  
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